SLC22A1 and cancer: Current understanding of resistance mechanisms include the ability of cancer cells to remove drugs (drug efflux) by the different transporters such as MDR1 (multidrug resistance protein 1) or P-glycoprotein, lack of bioavailability of drugs, and inhibition of transporter molecules such as SLC22A1 (solute carrier family 22 member 1), responsible for drug transport into the cell (drug influx), or mutations altering the interaction of drug with its target.